18 July 2016 - This Cost Recovery Implementation Statement provides information on how the TGA implements cost recovery activities associated with the registration and listing of medicines and inclusion of medical devices, including in vitro diagnostic devices, and biologicals onto the Australian Register of Therapeutic Goods and the ongoing monitoring and surveillance of them.

The TGA is a part of the Department of Health and contributes to Outcome 5 as outlined in the 2016-17 Portfolio Budget Statements.

Read Cost Recovery Implementation Statement